UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

Frontiers in oncology, 2020-07, Vol.10

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Drugs in context, 2020-01, Vol.9

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2019-11, Vol.25 (22), p.6623-6632

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2023-09, Vol.183, p.107313-107313, Article 107313

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2021-07, Vol.27 (13), p.3630-3640

2021

Link zum Volltext

Verfügbarkeit prüfen

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2023-07, Vol.116 (4), p.837-848

2023

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Cancer management and research, 2018-01, Vol.10, p.931-940

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of the Pregnant Patient with Breast Cancer

Southern medical journal (Birmingham, Ala.), 2017-10, Vol.110 (10), p.627

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer

Expert opinion on biological therapy, 2019-03, Vol.19 (3), p.225-232

2019

Link zum Volltext

Verfügbarkeit prüfen

372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A226-A227

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety monitoring practice during the initiation of tyrosine kinase inhibitors (TKIs) for NSCLC treatment

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21090-e21090

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Current treatment options in oncology, 2018-08, Vol.19 (8), p.39-17, Article 39

2018

Link zum Volltext

Verfügbarkeit prüfen

The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9102-9102

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9125-9125

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2019-07, Vol.24 (7), p.887-e416

2019

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2555-2555

2021

Link zum Volltext

Verfügbarkeit prüfen

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2021-02, Vol.109 (2), p.425-435

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3169-TPS3169

2019

Link zum Volltext

Verfügbarkeit prüfen

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis

Journal of Cancer, 2023-01, Vol.14 (17), p.3169-3175

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer

Clinical cancer research, 2019-08, Vol.25 (22), p.6623-6632

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT086-CT086

2019

Link zum Volltext

Verfügbarkeit prüfen

The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2662-TPS2662

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT191-CT191

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9567-9567

2020

Link zum Volltext

Verfügbarkeit prüfen

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3011-3011

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(81)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(27)
Humans
(24)
Biological And Medical Sciences
(11)
Female
(11)
Male
(11)
Medical Sciences
(11)
Oncology
(11)
Aged
(10)
Surgery
(10)
Middle Aged
(9)
Retrospective Studies
(9)
Technology
(7)
Treatment Outcome
(7)
Neoplasm Staging
(6)
Adult
(5)
Aged, 80 And Over
(5)
Aortic Aneurysm, Abdominal - Surgery
(5)
Chemotherapy
(5)
Clinical Trials
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer

A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Treatment of the Pregnant Patient with Breast Cancer

Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer

372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

Safety monitoring practice during the initiation of tyrosine kinase inhibitors (TKIs) for NSCLC treatment

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis

Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer

Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity

Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC)

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Suchergebnisse filtern